A Phase 2a Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group, Dose-Range Finding Study of MVT-602 in Healthy Premenopausal Women Undergoing Controlled Ovarian Stimulation (COS) Using a Minimal Stimulation Protocol.

开始日期2018-05-23

申办/合作机构

Myovant Sciences GmbH

NL-OMON44304

/ CompletedN/A

A Phase 1, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study of MVT-602 in Healthy Premenopausal Women - MVT-602-1001 (CS0288)

开始日期2017-10-30

申办/合作机构

Myovant Sciences GmbH

NCT02381288

/ Terminated临床2期

A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone

The purpose of this study is to evaluate the effects on serum testosterone (ST) after 6 weeks of subcutaneous (SC) administration of different doses and dosing frequencies of TAK-448 to middle-aged and older men with low ST levels.

开始日期2015-09-10

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

100 项与 MVT-602 相关的临床结果

登录后查看更多信息

100 项与 MVT-602 相关的转化医学

登录后查看更多信息

100 项与 MVT-602 相关的专利（医药）

登录后查看更多信息

项与 MVT-602 相关的文献（医药）

2024-08-16·Science Advances

Structural basis for the ligand recognition and G protein subtype selectivity of kisspeptin receptor

Article

作者: Han, Runyuan ; Chen, Jing ; Gao, Wei ; Wu, Zhangsong ; Du, Yang ; Pan, Xin ; Jiang, Shirui ; Chen, Geng ; Qiu, Chen ; Zhang, Binghao ; Ning, Peiruo ; Shi, Tingyi ; Yan, Xiaoyi ; Zhang, Zhiyi ; Ye, Fang ; Liu, Yiming ; Xu, Jun ; Wang, Qian ; Xu, Lezhi ; Li, Jiancheng

Kisspeptin receptor (KISS1R), belonging to the class A peptide-GPCR family, plays a key role in the regulation of reproductive physiology after stimulation by kisspeptin and is regarded as an attractive drug target for reproductive diseases. Here, we demonstrated that KISS1R can couple to the G i/o pathway besides the well-known G q/11 pathway. We further resolved the cryo–electron microscopy (cryo-EM) structure of KISS1R-G q and KISS1R-G i complexes bound to the synthetic agonist TAK448 and structure of KISS1R-G q complex bound to the endogenous agonist KP54. The high-resolution structures provided clear insights into mechanism of KISS1R recognition by its ligand and can facilitate the design of targeted drugs with high affinity to improve treatment effects. Moreover, the structural and functional analyses indicated that conformational differences in the extracellular loops (ECLs), intracellular loops (ICLs) of the receptor, and the “wavy hook” of the Gα subunit may account for the specificity of G protein coupling for KISS1R signaling.

2024-07-01·Cell Reports

Structural basis for hormone recognition and distinctive Gq protein coupling by the kisspeptin receptor

Article

作者: He, Xinheng ; Wang, Dongxue ; Cheng, Xi ; Shen, Shiyi ; Chen, Juanhua ; Cao, Yinglong ; Li, Shujie ; Xu, H Eric ; Liu, Heng ; Duan, Jia

Kisspeptin signaling through its G protein-coupled receptor, KISS1R, plays an indispensable role in regulating reproduction via the hypothalamic-pituitary-gonadal axis. Dysregulation of this pathway underlies severe disorders like infertility and precocious puberty. Here, we present cryo-EM structures of KISS1R bound to the endogenous agonist kisspeptin-10 and a synthetic analog TAK-448. These structures reveal pivotal interactions between peptide ligands and KISS1R extracellular loops for receptor activation. Both peptides exhibit a conserved binding mode, unveiling their common activation mechanism. Intriguingly, KISS1R displays a distinct 40° angular deviation in its intracellular TM6 region compared to other G_q-coupled receptors, enabling distinct interactions with G_q. This study reveals the molecular intricacies governing ligand binding and activation of KISS1R, while highlighting its exceptional ability to couple with G_q. Our findings pave the way for structure-guided design of therapeutics targeting this physiologically indispensable receptor.

2024-01-01·Fertility and sterility

Endocrine profile of the kisspeptin receptor agonist MVT-602 in healthy premenopausal women with and without ovarian stimulation: results from 2 randomized, placebo-controlled clinical tricals

Article

作者: Berman, Lance ; Ezzati, Max ; Migoya, Elizabeth ; Ufer, Mike ; Abbara, Ali ; Ferreira, Juan Camilo Arjona ; Lee, Tien-Yi ; Wu, Rui ; Dhillo, Waljit S ; Voors-Pette, Christine

BACKGROUND:

Kisspeptin is an essential regulator of hypothalamic gonadotropin-releasing hormone release and is required for physiological ovulation. Native kisspeptin-54 can induce oocyte maturation during in vitro fertilization treatment, including in women who are at high risk of ovarian hyperstimulation syndrome. MVT-602 is a potent kisspeptin receptor agonist with prospective utility to treat anovulatory disorders by triggering oocyte maturation and ovulation during medically assisted reproduction (MAR). Currently, the endocrine profile of MVT-602 during ovarian stimulation is unreported.

OBJECTIVE:

To determine the endocrine profile of MVT-602 in the follicular phase of healthy premenopausal women (phase-1 trial), and after minimal ovarian stimulation to more closely reflect the endocrine milieu encountered during MAR (phase-2a trial).

DESIGN:

Two randomized, placebo-controlled, parallel-group, dose-finding trials.

SETTING:

Clinical trials unit.

PATIENTS:

Healthy women aged 18-35 years, either without (phase-1; n = 24), or with ovarian stimulation (phase-2a; n = 75).

INTERVENTIONS:

Phase-1: single subcutaneous dose of MVT-602 (0.3, 1.0, or 3.0 μg) or placebo, (n = 6 per dose). Phase-2a: single subcutaneous dose of MVT-602 (0.1, 0.3, 1.0, or 3.0 μg; n = 16-17 per dose), triptorelin 0.2 mg (n = 5; active comparator), or placebo (n = 5).

MAIN OUTCOME MEASURES:

Phase-1: safety/tolerability; pharmacokinetics; and pharmacodynamics (luteinizing hormone [LH] and other reproductive hormones). Phase-2a: safety/tolerability; pharmacokinetics; pharmacodynamics (LH and other reproductive hormones); and time to ovulation assessed by transvaginal ultrasound.

RESULTS:

In both the trials, MVT-602 was safe and well tolerated across the entire dose range. It was rapidly absorbed and eliminated, with a mean elimination half-life of 1.3-2.2 hours. In the phase-2a trial, LH concentrations increased dose dependently; mean maximum change from baseline of 82.4 IU/L at 24.8 hours was observed after administration of 3 μg MVT-602 and remained >15 IU/L for 33 hours. Time to ovulation after drug administration was 3.3-3.9 days (MVT-602), 3.4 days (triptorelin), and 5.5 days (placebo). Ovulation occurred within 5 days of administration in 100% (3 μg), 88% (1 μg), 82% (0.3 μg), and 75% (0.1 μg), of women after MVT-602, 100% after triptorelin and 60% after placebo.

CONCLUSIONS:

MVT-602 induces LH concentrations of similar amplitude and duration as the physiological midcycle LH surge with potential utility for induction of oocyte maturation and ovulation during MAR.

CLINICAL TRIAL REGISTRATION NUMBER:

EUDRA-CT: 2017-003812-38, 2018-001379-20.

项与 MVT-602 相关的新闻（医药）

2022-10-24

·FierceBiotech

Sumitomo nets Myovant in $2.9B buyout, adding IVF asset to pipeline

A deal with Myovant will give Sumitomo control of a pipeline prospect, MVT-602. Sumitomo has landed its takeover target. After seeing Myovant turn down its original offer, the Japanese drugmaker has added almost 20% to its price to get the deal done and snag a phase 2 in vitro fertilization asset. Osaka-based Sumitomo became a major shareholder in Myovant in 2019 and, having seen its partner’s share price fall from above $20 to briefly below $10, made a move to buy the remaining 48% of the drug developer earlier this month. Myovant promptly knocked back the $22.75-a-share offer but left the door open to negotiations. Sumitomo returned with an offer of $27 a share and persuaded Myovant to sign. The deal centers on two commercial products, Orgovyx and Myfembree, but will also give Sumitomo control of a pipeline prospect, MVT-602. Takeda tried and failed to develop the oligopeptide kisspeptin-1 receptor agonist as a treatment for low levels of testosterone and other sex hormones. After missing the endpoints in phase 2 trials, Takeda offloaded the rights to the drug candidate as part of the deal with Roivant Sciences that birthed Myovant. While Takeda studied the molecule, then known as TAK-448, in men with sex hormone disorders, the new partners pitched it for use in female infertility at the time of their deal in 2016. Since then, Myovant has published phase 1 and phase 2a data on the candidate, linking it to a surge in luteinizing hormone associated with high and dose-dependent rates of ovulation. The company framed the data as evidence that MVT-602 could become a safe alternative egg-maturation trigger. Yet the progress of, and investment in, MVT-602 has stalled. In its 2021-22 financial year, Myovant racked up $318,000 in R&D costs specific to the candidate, down from $4.9 million in 2018-19. In theory, Sumitomo, a larger company, has the resources to kick-start development, but it made no mention of the molecule in its statement to disclose the Myovant merger.

并购

2022-10-18

·GlobeNewswire-Health Care

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 96,500 common shares of Myovant. One-fourth of the shares underlying each employee’s RSU will vest on the one-year anniversary of the grant date, with the balance of the common shares vesting in twelve equal quarterly installments thereafter, in each case, subject to each such employee’s continued employment with Myovant on such vesting dates. The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements. ABOUT MYOVANT SCIENCESMyovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to three regulatory approvals by the U.S. Food and Drug Administration (FDA) for men with advanced prostate cancer, women with heavy menstrual bleeding associated with uterine fibroids, and premenopausal women with moderate to severe pain associated with endometriosis, respectively. Myovant also has received regulatory approvals by the European Commission (EC) and the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with advanced hormone-sensitive prostate cancer. Myovant has a supplemental New Drug Application under review with the FDA for updates to the United States Prescribing Information (USPI) based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids for up to two years. Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. In addition, Myovant is developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit www.myovant.com. Follow @Myovant on Twitter and LinkedIn. Myovant Sciences ContactsInvestor Contact:Uneek MehraChief Financial and Business OfficerMyovant Sciences, Inc.investors@myovant.com Media Contact:Noelle Cloud DuganVice President, Corporate CommunicationsMyovant Sciences, Inc.media@myovant.com

2022-10-18

·BioSpace

Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08 - October 18, 2022

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 10 new employees with a grant date of October 17, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Company Manual Rule 303A.08. The new employees received, in the aggregate, restricted stock units (RSUs) to purchase 96,500 common shares of Myovant. One-fourth of the shares underlying each employee’s RSU will vest on the one-year anniversary of the grant date, with the balance of the common shares vesting in twelve equal quarterly installments thereafter, in each case, subject to each such employee’s continued employment with Myovant on such vesting dates. The RSUs are subject to the terms and conditions of the 2020 Inducement Plan and the applicable RSU agreements. ABOUT MYOVANT SCIENCES Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. Founded in 2016, Myovant has executed five successful Phase 3 clinical trials across oncology and women’s health leading to three regulatory approvals by the U.S. Food and Drug Administration (FDA) for men with advanced prostate cancer, women with heavy menstrual bleeding associated with uterine fibroids, and premenopausal women with moderate to severe pain associated with endometriosis, respectively. Myovant also has received regulatory approvals by the European Commission (EC) and the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) for women with symptomatic uterine fibroids and for men with advanced hormone-sensitive prostate cancer. Myovant has a supplemental New Drug Application under review with the FDA for updates to the United States Prescribing Information (USPI) based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in premenopausal women with heavy menstrual bleeding due to uterine fibroids for up to two years. Myovant also is conducting a Phase 3 study to evaluate the prevention of pregnancy in women with uterine fibroids or endometriosis. In addition, Myovant is developing MVT-602, an investigational oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is Myovant’s majority shareholder. For more information, please visit . Follow @Myovant on Twitter and LinkedIn. Myovant Sciences Contacts Investor Contact: Uneek Mehra Chief Financial and Business Officer Myovant Sciences, Inc. investors@myovant.com Media Contact: Noelle Cloud Dugan Vice President, Corporate Communications Myovant Sciences, Inc. media@myovant.com

100 项与 MVT-602 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11975

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
女性不孕症	临床2期	德国	Sumitomo Pharma Co., Ltd.	2020-10-26
低睾酮水平	临床2期	美国	Takeda Pharmaceutical Co., Ltd.	2015-09-10
肥胖	临床2期	英国	Takeda Pharmaceutical Co., Ltd.	2015-02-01
继发性睾丸衰竭	临床2期	英国	Takeda Pharmaceutical Co., Ltd.	2015-02-01
前列腺癌	临床2期	法国	Millennium Pharmaceuticals, Inc.	2010-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


OR33-4 (ENDO2019)	N/A	-	12	MVT-602	遞窪餘鹹築衊網廠膚觸(願構鹽簾範鏇顧鑰憲鹽) = 簾鏇繭顧膚夢餘蓋憲鹹遞鏇繭醖構築餘選衊簾 (憲選廠鬱壓糧獵艱願壓, 4.2) 更多	积极	2019-04-30
				KP54	遞窪餘鹹築衊網廠膚觸(願構鹽簾範鏇顧鑰憲鹽) = 願蓋構淵艱願蓋艱齋繭遞鏇繭醖構築餘選衊簾 (憲選廠鬱壓糧獵艱願壓, 5.3) 更多
SAT-211 (ENDO2019)	N/A	下丘脑闭经	15	MVT-602 (Women with Hypothalamic Amenorrhoea)	鬱積餘壓餘獵膚網餘艱(鬱鬱繭醖網網糧齋夢積) = 願壓願膚構選膚餘繭構壓憲選網鬱膚獵構窪構 (憲築鹽艱齋積觸獵範淵, 4.4) 更多	积极	2019-04-30
				MVT-602 (Healthy Women in Follicular Phase)	鬱積餘壓餘獵膚網餘艱(鬱鬱繭醖網網糧齋夢積) = 製鑰蓋鏇願網繭壓膚齋壓憲選網鬱膚獵構窪構 (憲築鹽艱齋積觸獵範淵, 1.6) 更多
NCT02381288 (CTgov)	临床2期	低睾酮水平	17	TAK-448 Placebo+TAK-448	醖築鹹餘網顧膚醖鹹顧(顧襯糧獵願衊艱淵醖醖) = 夢製觸醖糧鹹鹽鹽製憲鬱積築鏇積鹽窪獵壓憲 (構繭襯餘鬱膚鹽廠壓築, 29.186) 更多	-	2017-05-17
NCT02369796 (CTgov)	临床2期	继发性睾丸衰竭 \| 肥胖	15	TAK-448 (TAK-448 3 µg Once Weekly)	蓋憲構淵選醖範繭網膚(糧遞選夢窪鑰憲網積餘) = 遞顧網遞醖糧遞簾憲製淵鹽廠構膚鏇蓋壓鬱鏇 (觸鏇糧鑰築蓋遞繭築築, 11.3) 更多	-	2017-03-31
				TAK-448 (TAK-448 1 µg Once Weekly)	蓋憲構淵選醖範繭網膚(糧遞選夢窪鑰憲網積餘) = 觸齋蓋築餘選鹹顧憲選淵鹽廠構膚鏇蓋壓鬱鏇 (觸鏇糧鑰築蓋遞繭築築, 24.9) 更多